Mid-term outcomes of cardiovascular surgery for patients with Marfan syndrome.

Gen Thorac Cardiovasc Surg

Department of Cardiovascular Surgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan,

Published: May 2015

Objectives: Cardiovascular manifestations determine the prognosis and survival of patients with Marfan syndrome (MFS). We assessed the early and mid-term outcomes of cardiovascular surgery for this patient population.

Patients And Methods: We conducted a retrospective evaluation of patients with MFS who underwent surgery in our department. The endpoint was the requirement for a second cardiovascular surgery, and death from any cause.

Results: From February 2002 to March 2013, we performed 24 surgeries on 13 patients with MFS. At the time of initial surgery, the patients' aged ranged from 19 to 64 years of age (mean 34.7 ± 11.3 years) and included 5 men (38.5 %). Five of 13 initial surgeries (38.5 %) were emergencies. Seven patients (53.8 %) presented with aortic dissection at initial surgery, and one of the remaining six patients suffered from new aortic dissection during follow-up. Eight patients (61.5 %) underwent a second surgery, and a second surgery was not required for 100, 75.0, and 53.6 % of patients at 1, 3, and 5 years, respectively. The mean time interval between the first and the second surgeries was 52.8 ± 28.2 months. No patient died while hospitalized, and three subsequently died from unknown causes. Survival rates were 100, 90.9 and 64.9 % at 3, 5, and 7 years, respectively.

Conclusion: Although we obtained satisfactory early outcomes for patients with MFS, there were three late deaths from unknown causes. Therefore, we recommend that patients with MFS should remain under close surveillance.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11748-014-0507-6DOI Listing

Publication Analysis

Top Keywords

patients mfs
16
cardiovascular surgery
12
patients
10
mid-term outcomes
8
outcomes cardiovascular
8
surgery
8
patients marfan
8
marfan syndrome
8
initial surgery
8
aortic dissection
8

Similar Publications

Aim: To evaluate the efficacy of 25Gy/5# prophylactic pelvic nodal irradiation for regional control during stereotactic radiotherapy (SBRT) for high risk prostate cancer.

Methods: The multinational XXXX consortium database of patients treated with curative-intent prostate SBRT for high risk prostate cancer was queried for prophylactic radiotherapy 25Gy/5# to the pelvic lymph nodes. Details of Phoenix-defined biochemical failure, and location of recurrence (local, regional, or distant) were extracted.

View Article and Find Full Text PDF

Miller-Fisher syndrome (MFS) is characterized by the three major components of ophthalmoplegia, ataxia, and areflexia. The occurrence of MFS is relatively uncommon because of its monophasic nature, while recurrent Guillain-Barré syndrome (GBS) is a well-known condition. The pharyngeal-cervical-brachial (PCB) variant is a scarce variant of GBS (3%), which presents with muscle weakness initially involving the neck, oropharynx, and upper extremities.

View Article and Find Full Text PDF
Article Synopsis
  • Marfan syndrome (MFS) is a genetic disorder that affects connective tissue and often results in serious heart issues like aortic dilation and aneurysms.
  • A 35-year-old woman from Bangladesh with MFS experienced severe chest pain and had a significant aortic root aneurysm, leading to a dangerously low ejection fraction of 20%-25%.
  • An urgent Bentall procedure was performed to address the aortic dilation, which improved her condition, as her ejection fraction increased to 25% by the time she was discharged.
View Article and Find Full Text PDF

A novel therapeutic strategy for leukopenia: Miltefosine activates the Ras/MEK/ERK pathway to promote neutrophil differentiation.

Biochem Biophys Res Commun

December 2024

Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China. Electronic address:

Leukopenia, marked by diminished white blood cell (WBC) counts, presents significant challenges in the management of hematological malignancies and immunocompromised patients. This study evaluated the therapeutic potential of miltefosine (MFS), a phospholipid analogue, for treating leukopenia. In vitro studies using HL60 and NB4 cells revealed that MFS effectively promoted neutrophil differentiation and function, evidenced by the upregulation of surface markers CD11b, CD11c, CD14, and CD15, as well as enhanced bactericidal activity assessed through the NBT reduction assay.

View Article and Find Full Text PDF

Introduction: Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!